SG10201505374TA - Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant - Google Patents

Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Info

Publication number
SG10201505374TA
SG10201505374TA SG10201505374TA SG10201505374TA SG10201505374TA SG 10201505374T A SG10201505374T A SG 10201505374TA SG 10201505374T A SG10201505374T A SG 10201505374TA SG 10201505374T A SG10201505374T A SG 10201505374TA SG 10201505374T A SG10201505374T A SG 10201505374TA
Authority
SG
Singapore
Prior art keywords
adjuvant
virus
particle
composition
amyloid beta
Prior art date
Application number
SG10201505374TA
Other languages
English (en)
Inventor
Peter Ulrich
Katja Baer
Georges Imbert
Marie-Jose Hoellinger
Marie-Emmanuelle Riviere
Ana Graf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201505374T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201505374TA publication Critical patent/SG10201505374TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201505374TA 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant SG10201505374TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
SG10201505374TA true SG10201505374TA (en) 2015-08-28

Family

ID=42285305

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201505374TA SG10201505374TA (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
SG2012060554A SG183806A1 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012060554A SG183806A1 (en) 2010-03-29 2011-03-28 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Country Status (23)

Country Link
US (4) US20130011431A1 (ru)
EP (1) EP2552489A1 (ru)
JP (2) JP6088422B2 (ru)
KR (1) KR20130018407A (ru)
CN (2) CN102834118A (ru)
AR (1) AR080810A1 (ru)
AU (1) AU2011234656B2 (ru)
BR (1) BR112012024708A2 (ru)
CA (1) CA2793580A1 (ru)
CL (1) CL2012002685A1 (ru)
CO (1) CO6630127A2 (ru)
EC (1) ECSP12012180A (ru)
GT (1) GT201200265A (ru)
IL (1) IL221540B (ru)
MA (1) MA34084B1 (ru)
MX (1) MX2012011340A (ru)
NZ (1) NZ601729A (ru)
PE (1) PE20130642A1 (ru)
RU (1) RU2603486C2 (ru)
SG (2) SG10201505374TA (ru)
TN (1) TN2012000431A1 (ru)
TW (2) TW201138805A (ru)
WO (1) WO2011120924A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
PT3137093T (pt) * 2014-04-29 2017-12-19 Affiris Ag Tratamento e prevenção da doença de alzheimer (da)
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
EP1006999A2 (en) * 1997-07-08 2000-06-14 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
EP1524994B1 (en) * 2002-07-19 2011-04-27 Cytos Biotechnology AG Vaccine compositions containing amyloid beta1-6 antigen arrays
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
EP1791870A1 (en) * 2004-09-21 2007-06-06 Cytos Biotechnology AG Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
CA2793580A1 (en) 2011-10-06
ECSP12012180A (es) 2012-10-30
WO2011120924A1 (en) 2011-10-06
US20140348871A1 (en) 2014-11-27
RU2603486C2 (ru) 2016-11-27
JP2017008035A (ja) 2017-01-12
SG183806A1 (en) 2012-10-30
US20160101167A1 (en) 2016-04-14
JP2013523682A (ja) 2013-06-17
PE20130642A1 (es) 2013-06-19
US20130011431A1 (en) 2013-01-10
IL221540B (en) 2018-11-29
KR20130018407A (ko) 2013-02-21
TW201618806A (zh) 2016-06-01
JP6088422B2 (ja) 2017-03-01
CL2012002685A1 (es) 2013-01-25
NZ601729A (en) 2013-10-25
CN104436212A (zh) 2015-03-25
GT201200265A (es) 2014-03-14
MA34084B1 (fr) 2013-03-05
EP2552489A1 (en) 2013-02-06
US20150297692A1 (en) 2015-10-22
TN2012000431A1 (en) 2014-01-30
AU2011234656A1 (en) 2012-10-11
RU2012145734A (ru) 2014-05-10
CN102834118A (zh) 2012-12-19
AR080810A1 (es) 2012-05-09
MX2012011340A (es) 2012-11-16
AU2011234656B2 (en) 2013-08-01
BR112012024708A2 (pt) 2016-06-07
TW201138805A (en) 2011-11-16
CO6630127A2 (es) 2013-03-01

Similar Documents

Publication Publication Date Title
IL285226A (en) Antibodies against amyloid beta peptide n3pglu and their uses
GB201400609D0 (en) Vaccine adjuvant composition comprising inulin particles
EP2547373A4 (en) NANOTUBES AND ASSOCIATED COMPOSITIONS
SG10201505374TA (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
EP2542347A4 (en) APPARATUS FOR PRECIPITATION OF PARTICLES
EP2538969A4 (en) VACCINES FROM POLYSACCHARIDE PARTICLES
ZA201304201B (en) Composition comprising insecticide-wax particles
GB201003333D0 (en) Immunogenic proteins and compositions
PL2380962T3 (pl) Cząstka
EP2575869A4 (en) PEPTIDE PARTICLE FORMULATION
ZA201303886B (en) Tomm34 peptides and vaccines including the same
HK1177138A1 (en) Vaccine compositions based on sticholysin encapsulated in liposomes
EP2604671A4 (en) SILICATE LUMINESCENT MATERIALS AND METHODS FOR PREPARING SAME
IL221474A0 (en) Hjurp peptides and vaccines including the same
EP2653518A4 (en) HALOGENATED SILICATE FLUORESCENT MATERIALS AND PROCESSES FOR PREPARING THE SAME
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them
EP2590621A4 (en) WELD-INHIBITABLE COMPOSITIONS AND PRODUCTION METHOD THEREFOR
AU2010900937A0 (en) Particle precipitator
TWM390824U (en) Crushed material cleaner